<img src="http://www.npicenter.com/images/MarcUllman.gif" border="0" align="left">Mr. Ullman speaks frequently on various regulatory matters at various events, including Virgo Publications' Natural Products Industry Supply Side West Trade Shows and the National Nutritional Foods Association's annual MarketPlace Convention. He also manages the FYI Newsletter highlighting legal and regulatory issues concerning the Natural Product Industry. <br><br>Marc is a partner in New York City based Ullman, Shapiro & Ullman, <a href="http://www.usulaw.com">www.usulaw.com</a>. You can contact him at Marc[at]usulaw.com<br><br><i>Please note that blog is not intended to provide or serve as legal advice of any kind, and that the reader should not rely on it for such advice.</i> http://www.npicommunity.com/Blogs/tabid/53/BlogId/1/Default.aspx en-US marc@usulaw.com sa@sa.sa Wed, 07 Jan 2009 05:10:45 GMT Wed, 07 Jan 2009 05:10:45 GMT http://backend.userland.com/rss Blog RSS Generator Version 3.1.20.17153 On October 16, 2001 FDA sent Warning Letters to two companies marketing combination dietary supplement/OTC drug products, stating that those products were “unapproved new drugs” and requesting “corrective action” within 15 days. Pharmaceutical giant Bayer Healthcare, LLC has recently launched a combination aspirin phytosterol product. Have the rules changed? http://www.npicommunity.com/Blogs/tabid/53/EntryID/114/Default.aspx marc@usulaw.com http://www.npicommunity.com/Blogs/tabid/53/EntryID/114/Default.aspx#Comments http://www.npicommunity.com/Default.aspx?tabid=53&EntryID=114 Tue, 20 May 2008 20:37:00 GMT 0 http://www.npicommunity.com/DesktopModules/Blog/Trackback.aspx?id=114